GOAL II
- Gender
- Women and men
- Age
- 18–64 years
- Trial type
- Interventional
- Line of therapy
- Relapsed / refractory
- Phase
- Phase II
What is this trial about?
The GOAL-II trial is investigating the efficacy of adding a new antibody to existing standard therapy in patients with relapsed aggressive lymphoma.
Detailed description
Patients with a relapse of aggressive lymphoma who are not eligible for intensive therapy, or for whom no curative options are available, may be treated in this study. According to current clinical practice, these patients are treated with what is known as chemoimmunotherapy (antibodies in combination with chemotherapy). The study aims to investigate whether adding this additional antibody leads to improved efficacy.
Trial sites
27 trial sites in Germany are listed. Find a site near you.
Universitätsklinikum Augsburg
Stenglinstrasse 2, 86156 Augsburg
Active, not recruitingSt. Johannes Hospital Dortmund
Amalienstraße 21a, 44137 Dortmund
Status unknownStädtisches Klinikum Dresden
Dresden
Status unknownStudienzentrum
Frankfurt a.M.
Status unknownUniversitätsklinikum Frankfurt
Theodor-Stern-Kai 7, 60590 Frankfurt am Main
Active, not recruitingKlinikum Fulda
Pacellialle 4, 36043 Fulda
Status unknown
This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.
- Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
- PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine
This description was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.